Edoxaban Approved in US with Restriction on Use; Impact on Daiichi Sankyo’s Midterm Business Plan Remains Unclear

Daiichi Sankyo expects the anticoagulant edoxaban to play a key role in helping it achieve the targets in its midterm business plan. Edoxaban was approved on January 8 in the US under the brand name Savaysa. However, the product label...read more